GOSOGLIPTIN

/static/temp/default.svg

Search structure


Synonyms	Gosogliptin PF-00734200 PF-734,200 PF-734200
Status
Molecule Category	UNKNOWN
UNII	GI718UO477


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QWEWGXUTRTXFRF-KBPBESRZSA-N
Smiles	O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1
InChI	InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H24F2N6O
Molecular Weight	366.42
AlogP	0.2
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	64.6
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	26.0

Bioactivity

Mechanism of Action	Action	Reference
Dipeptidyl peptidase IV inhibitor	INHIBITOR	PubMed


Protein: Dipeptidyl peptidase IV Description: Dipeptidyl peptidase 4 Organism : Homo sapiens P27487 ENSG00000197635

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Protease Serine protease Serine protease SC clan Serine protease S28 family	-	3300	-	-	-
Enzyme Protease Serine protease Serine protease SC clan Serine protease S9B subfamily	-	11-13	-	-	-
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel	-	-	-	-	15

Assay Description	Organism	Bioactivity	Reference
Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells at 10 uM	Homo sapiens	14.9 %
Inhibition of human recombinant DPP4	Homo sapiens	12.9 nM
Inhibition of human plasma DPP4	Homo sapiens	11.3 nM
Inhibition of rat plasma DPP4	Rattus norvegicus	12.8 nM
Ex vivo inhibition of DPP4 in Sprague-Dawley rat	Rattus norvegicus	0.0013 ug.mL-1
Inhibition of dipeptidyl peptidase 4 (unknown origin)	Homo sapiens	12.9 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL515387
DrugBank	DB08382
FDA SRS	GI718UO477
Guide to Pharmacology	7413
PDB	PF2
PubChem	11516136
SureChEMBL	SCHEMBL197108
ZINC	ZINC000023247686

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).